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Abstract
Background: The aim of this investigator-initiated trial is to evaluate the safety and efficacy of the novel Luminor®
paclitaxel-coated drug-eluting balloon (DEB) catheter (iVascular, S.L.U., Barcelona, Spain) in inhibiting restenosis and
in ensuring long-term vascular patency.
Methods/design: This is a multicenter randomized controlled trial to evaluate the Luminor® paclitaxel-coated DEB
catheter for stenotic or occlusive lesions (length ≤15 cm) in the superficial femoral artery (SFA) and the popliteal
artery (PA) up to the P1 segment compared to the noncoated, plain old balloon angioplasty (POBA) catheter. In
total 172 subjects will be treated with either the DEB catheter or the POBA catheter in 11 German study centers in
a 1:1 randomization study design. The primary endpoint is late lumen loss (LLL) at 6 months. Secondary endpoints
are patency rate, target lesion/vessel revascularization, quality of life (assessed with the Walking Impairment
Questionnaire (WIQ) and the EQ-5D), change of Rutherford stage and ankle-brachial index, major and minor
amputation rate at the index limb, number of dropouts and all-cause mortality.
Discussion: EffPac represents a randomized controlled trial that will provide evidence on the effectiveness of
the Luminor® paclitaxel-coated DEB catheter for the reduction of restenosis compared to the POBA catheter
for the SFA and the PA. The results of EffPac will allow direct comparison to other already-completed RCTs
applying paclitaxel-coated DEBs from different manufacturers with different coating technologies in the same
target vessel.
Trial registration: ClinicalTrials.gov Identifier: NCT02540018, registered on 17 August 2015.
Protocol version: CIP Version Final04, 11 February 2016.
EUDAMED No: CIV-15-03-013204.
* Correspondence: ulf.teichgraeber@med.uni-jena.de
1Universitätsklinikum Jena, Institut für Diagnostische und Interventionelle
Radiologie, Am Klinikum 1, 07747 Jena, Germany
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Teichgräber et al. Trials  (2016) 17:528 
DOI 10.1186/s13063-016-1657-x
Background
The Luminor® paclitaxel-coated drug-eluting balloon (DEB)
catheter (iVascular, S.L.U., Barcelona, Spain) is specially
designed for the percutaneous transluminal angioplasty
(PTA) technique. The DEB catheter is based on a pro-
prietary Transfertech® coating technology. This has
been engineered to improve clinical efficacy by optimizing
coating properties and device functionalities. It allows a
homogeneous and precise paclitaxel concentration of
3 μg/mm2 on the PTA balloon surface. This patient-
blinded randomized controlled trial (RCT) focuses on
the efficacy and the clinical outcome of the Luminor®
paclitaxel-coated DEB catheter.
Experience in animal models has shown that paclitaxel-
coated DEB catheters demonstrate an inhibition of
neointimal hyperplasia after PTA [1]. The safety issue
of paclitaxel-coated DEB catheters has been well-investigated
in clinical studies for the use in femoropopliteal arteries using
paclitaxel-coated DEB catheters from other manufac-
turers, with drug concentrations ranging from 2.0 to
3.5 μg/mm2 on the PTA balloon surface [2]. The
THUNDER and FemPac RCTs used the iopromide-matrix-
coated Paccocath® catheter with comparable study designs.
The results of both trials demonstrated that the paclitaxel-
coated DEB catheter offered superior restenosis inhibition
and reduced target lesion revascularization (TLR) rates in
the femoropopliteal artery [3, 4]. These results were con-
firmed with IN.PACT Pacific® urea-matrix-paclitaxel-coated
DEB catheters in the same target vessel [5].
The EffPac study design follows the Trans-Atlantic Inter-
Society Consensus – II (TASC II), which provides com-
prehensive, evidence-based recommendations for vascular
practice and treatment decisions between endovascu-
lar and surgical techniques. According to the TASC II
on femoropopliteal lesions, endovascular therapy is
the treatment of choice for type A lesions (single occlu-
sion ≤5 cm) and is the preferred treatment for type B le-
sions (occlusions ≤15 cm) (Recommendation No. 37) [6].
The EffPac trial will include both TASC II type A and type
B lesions.
Study hypothesis
That Luminor® paclitaxel-coated balloon catheters will be
associated with significantly lower reocclusion and resten-
osis rates as compared to noncoated, plain old bal-
loon angioplasty (POBA) catheters in both TASC II type A
and type B lesions (≤15 cm) of the superficial femoral artery
(SFA) and the proximal popliteal artery (PA).
Methods
Study design
EffPac is designed as a randomized controlled, multicenter
trial in which the Luminor® paclitaxel DEB catheter is com-
pared to the POBA catheter in de novo stenotic/restenotic
or occlusive lesions in the SFA and/or proximal PA to pre-
vent vessel restenosis or reocclusion (Fig. 1). The clinical
endpoints used for classification focus primarily on effect-
iveness, followed by safety monitoring and side effects.
Study setting
The University Hospital Jena, as the coordinating study
center, is an academic hospital with intense research
activity. The other 10 study sites are located on German
national territory. The detailed list of study sites can be
accessed at (NCT02540018).
Primary endpoint
The primary endpoint of EffPac trial is the late lumen
loss (LLL), defined angiographically as the difference be-
tween the intraluminal vessel diameter (in mm) at
6 months follow-up (FU) and the diameter measured
immediately post procedure.
Secondary endpoints
 Occurrence of restenosis at follow-up (FU) (defined as
incidence of stenosis ≥50 %) (6 months and 12 months)
 Freedom from target lesion revascularization (TLR)
at FU (6 months and 12 months)
 Freedom from target vessel revascularization (TVR)
at FU (6 months and 12 months)
 Change of Rutherford stage at baseline and at FU:
(0) asymptomatic, (1) mild claudication, (2)
moderate claudication, (3) severe claudication, (4)
ischemic rest pain, (5) minor tissue loss, (6)
ulceration or gangrene
 Change of ankle-brachial Index (ABI) from baseline
at FU (6 months and 12 months)
 Change in quality of life according to the WIQ and
the EuroQoL 5 dimensions questionnaire (EQ-5D)
from baseline at FU (6 months and 12 months)
 Major and minor amputation rate at the index limb
 Number of dropouts
 All-cause mortality
Definitions
LLL as the primary efficacy endpoint was not designated
as a safety issue, and allows researchers to evaluate the
efficacy of paclitaxel-coated DEB angioplasty as a drug
device in inhibiting restenosis and reocclusion of target
lesions in the SFA. LLL is defined as the angiographic
minimum lumen diameter (MLD) immediately after
PTA minus the MLD at angiographic follow-up (Fig. 2).
The LLL represents a measure that corresponds to neo-
intimal growth inhibition and it predicts TLR occurrence
[7]. TLR is defined as a clinically driven repeated percu-
taneous intervention of the target lesion or bypass sur-
gery of the target vessel.
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Patients
A total of 172 patients (reflecting a 10 % loss to follow-up)
with stenosis or occlusion of the SFA and PA, to be ran-
domly assigned to study groups.
Eligibility criteria
Ages eligible for study: 18 years and older.
Genders eligible for study: both.
Acceptance of healthy volunteers: no.
Inclusion criteria
The subject must meet all of the following general inclusion
criteria:
1. Age ≥18 years
2. Subject must agree to undergo the 6-month
angiographic FU as well as the clinical FU (at 6- and
12-months post procedure)
3. Peripheral vascular disease Rutherford classes 2–4
4. De novo stenotic/restenotic lesion or occlusive
lesions in the SFA and/or proximal PA
Fig. 1 Flow diagram for indication, treatment and follow-up
Fig. 2 Late lumen loss (LLL) is defined as the angiographic minimum
lumen diameter (MLD) immediately after percutaneous transluminal
angioplasty (PTA) minus the minimum lumen diameter (MLD) at
angiographic follow-up
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5. If the index lesion is restenotic, the prior PTA must
have been more than 30 days prior to treatment in
the current study
6. At least 70 % diameter stenosis or occlusion
7. Target lesion length: ≤15 cm (TASC II types A and B)
8. Only one lesion per limb and per patient can be treated
9. At least one patent infrapopliteal run-off artery to the
foot of the index limb
10.Successful endoluminal guidewire passage through
the target lesion
11.Predilatation prior to randomization
12.Life expectancy, in the investigators’ opinion, of at
least 1 year
13.Subject is able to verbally acknowledge and understand
the aim of this trial and is willing and able to provide
informed consent
Exclusion criteria
The subject must not meet any of the following general
exclusion criteria:
1. Previous surgery in the target vessel
2. Patients who require a PTA balloon catheter of
diameter size 4 mm and below or diameter size
above 7 mm
3. Major amputation in the same limb as the target
lesion
4. Acute myocardial infarction within 30 days before
intervention
5. Severely calcified target lesions in the SFA/PA
resistant to PTA
6. Subjects requiring different treatment or raising
serious safety concerns regarding the procedure or
the required medication
7. Women of childbearing potential, except women
meeting the following criteria:
 Post-menopausal (12-month natural amenorrhea or
6-month amenorrhea with serum FSH >40 mlU/ml)
 Sterilization 86 weeks after bilateral ovariectomy
with or without hysterectomy
 Using an effective method of birth control for the
duration of the trial: implants, injectables, combined
oral contraceptives, intrauterine device (in place for
a period of at least 2 months prior to screening) and
with a negative serum pregnancy test
 Sexual abstinence
 Vasectomized partner
8. Pregnant and nursing women
9. Acute thrombus or aneurysm in the index limb or
vessel (presence of stent in the target lesion)
10.In-stent restenosis in the target lesion
11.Renal insufficiency with a serum creatinine >2.0 mg/dl
at baseline
12.Platelet count <50 G/l or >600 G/l at baseline
13.Known hypersensitivity or contraindication to contrast
agent that cannot be adequately premedicated
14.Subjects with known allergy to paclitaxel
15.Subjects with intolerance of antiplatelet, anticoagulant,
or thrombolytic medications that would be
administered during the trial
16.Dialysis or long-term immunosuppressant therapy
17.Current participation (or within the last 3 months)
in another interventional study
18.Treatment of in-stent restenosis of target lesion is
not allowed, but treatment of in-stent restenosis
outside of target lesion in the target vessel is not
an exclusion criterion
Recruitment
All compliant patients undergoing angioplasty to the SFA
and PA are accurately informed about the trial in a prescre-
ening phase. The study nurse visits the eligible patient on
the ward or at the outpatient clinic and explains to them
the objectives and procedures that are relevant to the study
and hands them information material such as the study
flyer. If the patient gives consent to participate in the EffPac
trial, the investigator is responsible for obtaining written in-
formed consent from the patient after adequate explanation
of all aspects of the trial that are relevant for the patients’
decision to participate. Before participation in the study,
the investigator must also inform the patients that they are
completely free to refuse to enter the study or to withdraw
from it at any time and for any reason. The patient is en-
rolled in the study after it has been determined that they
meet all the inclusion criteria and none of the exclusion cri-
teria. The investigator enrolls the patients and assigns the
participants to intervention.
Safety and quality control
A Data and Safety Monitoring Board (DSMB) is established
in order to protect the safety, rights and wellbeing of study
participants. The DSMB consists of a group of two inde-
pendent physicians and a statistician with pertinent expert-
ise who review and adjudicate important endpoints and
relevant adverse events reported by the study investigators.
The DSMB members serve as an advisory panel to the
study investigators.
Compensation for post-trial care, for those patients
who suffered harm from trial participation, is covered by
a trial health insurance.
Confidentiality
The investigators and the study staff will keep all infor-
mation provided by the sponsor and about the study pa-
tients in strict confidence. For protection of these data,
organizational procedures are implemented to prevent
their distribution to unauthorized persons. Appropriate
local data legislation will be fulfilled in its entirety.
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Financial disclosure
All investigators must sign the study protocol acceptance
and the financial disclosure form.
Medications
Patients will receive dual antiplatelet therapy (DAPT) dur-
ing a period of at least 4–6 weeks after angioplasty, if toler-
ated. The typical, recommended DAPT regimen consists of
acetylsalicylic acid (ASA) (minimum 75 mg/day) and a
P2Y12 inhibitor, e.g., clopidogrel (minimum 75 mg/day).
Alternate DAPT regimens may be followed if justified by
individual patient requirements, e.g., if there is documented
intolerance to any of these drugs, or the patient is already
taking a different antiplatelet therapy (with at least two ap-
proved drugs) due to comorbid conditions. The investigator
will be guided by the drug manufacturer’s instructions,
available scientific evidence and medical guidelines applic-
able to patients with peripheral arterial disease.
After 4–6 weeks of DAPT post procedure, patients
will receive at least one antiplatelet drug indefinitely.
Patients receiving anticoagulant therapy should not re-
ceive additional antiplatelet drugs if, in the opinion of
the investigator, this could present an intolerable bleed-
ing risk.
Patients who do not take already DAPT drugs at admis-
sion should receive an appropriate periprocedural loading
doses. Recommended minimum loading doses are 300 mg
for ASA and 300 mg for clopidogrel. At least one antiplate-
let drug is administered prior to the angioplasty, and the
second antiplatelet drug should be administered within 2 h
post procedure if not given beforehand. At the time of the
procedure, patients should receive an intra-arterial bolus of
heparin (usually 5000 IU), or alternate anticoagulants as
substitutes for heparin if justified by individual patient re-
quirements. The typical, recommended DAPT and anticoa-
gulation regimen must be consistently followed for both
study and control devices.
Adverse and serious events
An adverse event (AE) is any untoward medical occur-
rence in a subject that occurs in conjunction with the
use of the study device, whether or not the event is
considered device-related.
New and worsening signs and symptoms of under-
lying or emerging disease must be recorded as adverse
events.
Adverse events may include, but are not limited to:
 Subjective or objective symptoms spontaneously
reported by the patient or subject and/or observed
by the investigator or medical staff
 Laboratory, electrocardiogram (ECG) or physical
examination abnormalities of clinical significance
or for which a medical intervention was initiated
A serious adverse event (SAE) or serious adverse device
effect (SADE) is defined as an AE or adverse device effect
(ADE) that results in any of the following outcomes:
 Death,
 A life-threatening adverse event,
 Inpatient hospitalization or prolongation of existing
hospitalization,
 A persistent or significant disability/incapacity
 A congenital anomaly/birth defect
Important medical events that may not result in death,
be life-threatening, or require hospitalization may be
considered a SAE when, based upon appropriate medical
judgment, they may jeopardize the subject and may re-
quire medical or surgical intervention to prevent one of
the outcomes listed in the definition above.
All AEs during the safety observation period, whether
considered associated with the use of the study endovas-
cular device or not, must be monitored until symptoms
subside or return to baseline, or until there is a satisfac-
tory explanation for the changes observed. Follow-up in-
formation will be submitted to the study sponsor as it
becomes available.
The safety observation period starts with successful
randomization and ends at the 12-month follow-up
(visit 3).
Statistical analysis
All analyses of primary and secondary endpoints follow
the intention-to-treat (ITT) principle and are performed
for all participants based on the group to which they
were randomly allocated. Multiple imputation of missing
values will be conducted for the primary endpoint to
evaluate the robustness of the conclusions.
Sample size
The primary objective of the trial is to show that LLL in
the paclitaxel-coated DEB catheter group is less than
that in the POBA catheter group.
In a pilot trial by Werk et al. [3], average lumen loss
after 6 months was 0.5 mm (SD = 1.1 mm) in the coated
balloon group and 1.0 mm (SD = 1.1 mm) in the uncoated
balloon group. At a 5 % significance level, a two-sided
independent samples t test will have an 80 % power to
detect an effect size of 0.45 when the sample size in each
group is 77 (nQuery Advisor 7.0). Taking into account a
dropout rate for primary endpoint data of 10 %, a total of
172 patients should be randomized.
Data analysis plan
The primary endpoint will be analyzed by a linear mixed
model with fixed effect of the treatment and random
center effects.
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Kaplan-Meier curves will be estimated for the secondary
endpoints of mortality and minor and major amputations.
The survival curves of the treatment groups are compared
using the log-rank test.
For Rutherford stage, the change in class number
between baseline and follow-up will be calculated for
each patient. To compare both treatment groups re-
garding the change, Cochran-Mantel-Haenszel statis-
tics will be applied.
Change of ABI and “Quality of Life” according to the
EQ-5D and the WIQ will be compared between the
treatment groups by an independent sample t test or a
nonparametric Mann-Whitney U test according to the
data distribution. Frequency of restenosis, number of
dropouts, TLR and TVR will be compared by Fisher’s
exact test between groups.
Study schedule
Visit 0: (baseline period/screening)
The screening process will be used to determine the inclu-
sion or exclusion of a patient in the study. After the patient
has signed the informed consent form, the screening
process may begin.
This process includes the investigator’s assessment of
the patient’s medical records and diagnosis, including:
 Demographic data: gender, date of birth, height,
weight, smoking status
 Medical history: (including concomitant diseases
(hypertension, hyperlipidemia, diabetes mellitus,
renal insufficiency, angina pectoris, arrhythmia,
stroke, congestive heart failure, coronary arterial
disease, transient ischemic attack, myocardial
infarction)
 Concomitant medication and medical treatments
 Anticoagulants
 Physical assessment
 Routine laboratory tests (with pregnancy test in
women with childbearing potential)
 Duplex ultrasound (DUS) of the pelvic and lower-limb
arteries – optional (according to the physician’s
decision)
 EQ-5D and Walking Impairment Questionnaire
(WIQ)
 Ankle-brachial Index (ABI)
 Rutherford stage assessment
Visit 1: treatment (angioplasty)
The balloon dilatation procedure, including deployment
to the target lesion and balloon inflation, deflation and
retrieval, is performed under fluoroscopic observation.
All sites will have access to an emergency unit to en-
able interventions to be converted to bypass surgery,
e.g., in case of failed PTA. The patient is positioned on
the angiographic table and draped in a sterile fashion.
The standard vascular access accords with the ipsilat-
eral or contralateral femoral artery in relation to the
target vessel. The endovascular procedure can be per-
formed in a direct antegrade or a crossover retrograde
technique.
An introducer sheath will be inserted over a guidewire.
Five thousand I.U. heparin is injected intra-arterially (i.a.)
to prevent periprocedural thrombotic events. Alternative
periprocedural anticoagulation regimens may be applied if
justified by individual patient requirements. Endoluminal
guidewire passage through the stenotic and occlusive
femoropopliteal lesion is mandatory for study inclusion.
A POBA PTA balloon of appropriate balloon diameter
and length and catheter working length is selected ac-
cording to the characteristics of the target vessel and the
lesion for predilatation and assessment by angiography
(digital subtraction angiography (DSA) or X-ray angiog-
raphy (XA)). A ruler must be placed adjacent to the target
vessel for accurate measuring.
Predilatation in both study arms with POBA catheters:
 Inflation time minimum 30 s (without limit above)
 PTA balloon inflation up to nominal pressure
 Diameter of POBA catheter according to reference
measurement directly proximal to the lesion
 Length of POBA catheter with 10 mm overlap
proximal and distal to the lesion
 Repeated predilatations (up to three) with the same
POBA catheter is allowed in case of PTA-resistant
stenosis
After predilatation of the target lesion, an angiographic
assessment will be performed (DSA or XA). Again, a
ruler must be placed adjacent to the target vessel for
accurate measuring. The treatment group represents
the Luminor® DEB catheter and the control group the
POBA catheter using a CE-marked non-drug-eluting PTA
balloon catheter.
Randomization occurs only after the target lesion has
been successfully crossed by a guidewire and there is
fulfillment of angiographic inclusion/exclusion criteria.
Randomization will be performed by sealed envelope
pull. Due to the nature of the study, the investigator
will not be blinded to the treatment allocation. The
allocation is patient-blinded. Unblinding is only permis-
sible if knowledge of the study treatment is absolutely
essential for further management of the patient.
For both Luminor 35® paclitaxel-coated DEB angioplasty
(experimental group) and the POBA catheter (control
group), identical procedures for both study arms will be
adopted:
 Inflation time 60 ± 10 s
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 PTA balloon inflation up to nominal pressure
 Diameter of PTA balloon catheter should be sized ≥1:1
according to reference vessel diameter measurement
directly proximal to the lesion
 Length of PTA catheter with 10 mm overlap
proximal and distal to the lesion
 The longest possible adaptable balloon must be used
for the lesion. If this is not applicable, overlapping is
allowed
 In case two or multiple DEB catheters are used a
minimal overlap of 5 to 10 mm is required
After dilatation of the target lesion, the PTA catheter
is withdrawn through the introducer sheath and a post-
PTA angiogram is performed (DSA or XA) to evaluate the
technical result and possible procedural complications. A
final run-off angiogram (DSA or XA) of the BTK (below
the knee) arteries is required.
In case of a nonflow-limiting or flow-limiting dissection,
a prolonged PTA with the same PTA balloon is required.
If the flow-limiting dissection persists, the required drop-
out stenting is not an exclusion criterion (Fig. 3).
If stenting is necessary, stent grafts (covered stents) or
drug-coated stents (heparin, paclitaxel, etc.) cannot be used.
Visit 2: 1. Follow-up (6-month follow-up (±30 days))
The 6-month follow-up is an in-person visit and the
following data will be collected:
 Angiographic assessment/quantitative vascular
analysis (QVA) (primary endpoint: LLL) (if further
treatment becomes necessary, drug-eluting stent
(DES) or DEBs should not be used, only POBA
catheters)
 DUS to identify the occurrence of restenosis
 Medication
 TLR/TVR
 ABI
 Rutherford stages
 WIQ, EQ-5D
 AEs/SAEs
Visit 3: 2. Follow-up (12-month follow-up (±30 days))
The 12-month follow-up is an in-person visit and the
following data will be collected:
 DUS to identify the occurrence of restenosis
 Medication
 TLR/TVR
 ABI
 Rutherford stages
 WIQ, EQ-5D
 AEs/SAEs
To promote follow-up completion, the study nurse is in
continuous contact with the study patients and in timely
fashion sends letters to invite patients to the follow-up
visits.
A schedule of enrollment, interventions and assessments
for the EffPac trial following Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) is
summarized in Table 1.
Fig. 3 Randomization and angioplasty
Teichgräber et al. Trials  (2016) 17:528 Page 7 of 11
Monitoring and reporting
The sponsor or the appointed Clinical Research Organization
(CRO) is responsible for the monitoring activities. The site
initiation, monitoring and close-out visits in general
will be performed on site. The purpose of the monitor-
ing is primarily to ensure the protection of the rights
and safety of the participating subjects. After the moni-
toring visits a detailed report will be created. Protocol
deviations that occur, such as AEs and SAEs, are
discussed with the investigator and reported to the sponsor
within 24 h. Furthermore, the monitoring is to ensure good
data quality and a continuing conduction of the clinical trial
in accordance with the CIP, ISO 14155, the ICH-GCP and
the Declaration of Helsinki.
Data collection
For each randomized patient an electronic Case Report
Form (CRF) will be completed. Data capture takes place
Table 1 Schedule of enrollment, interventions and assessments for the EffPac trial
Study period
Enrollment Allocation Post allocation Close-out
Time pointa −t1 0 t1 t2 t3 tx
Enrollment:
Prescreening X
Eligibility screen X
Informed consent X
Allocation X
Interventions:
Intervention DEB catheter X
Control group POBA catheter X
Assessmentsb:
List baseline variables:
XA/DSA
X X X
Duplex ultrasound (DUS) X X X
Freedom from TLR/TVR X X X
Rutherford stage X X X
ABI X X X
WIQ X X X
EQ-5D X X X
AE X X X
SAE X X X
Primary endpoint:
LLL
X
Secondary endpoints:
Occurrence of restenosis
X X X
Freedom of TLR X X X
Freedom of TVR X X X
Change of Rutherford X X X
Change of ABI X X X
Patency (DUS) X X X
Change of QoL
(WIQ and EQ-5D)
X X X
Amputation rate X X X
Dropouts X X X
Mortality X X X
a−t1 screening and enrollment, t1 baseline (visit 0), t2 follow-up 1 after 6 months (visit 1), t3 follow-up 2 after 12 months (visit 2), tx close-out = end of follow-up 2
bABI Ankle-brachial Index, AE adverse events, DEB drug-eluting balloon, DSA digital subtraction angiography, LLL late lumen loss, POBA plain old angioplasty
balloon, QoL quality of life, SAE serious adverse events, TLR target lesion revascularization, TVR target vessel revascularization, US ultrasound, WIQ Walking Impairment
Test, XA X-ray angiography
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via web application on the servers of the Center for
Clinical Studies at Jena University Hospital with “Open-
Clinica®”, a study management software. OpenClinica®
meets all regulatory requirements (GCP, 21CFR Part 11).
Patient files and other source data (particularly with
regard to informed consent, date of X-rays and outcome)
must be kept for the maximum period of time permitted
by the hospital or institution, but at least 30 years. The
sponsor of the trial must keep all other documentation
pertaining to the trial for at least 15 years.
Auditing
All local and national regulations are observed. This in-
cludes an audit by the sponsor’s representatives during
the course of the study. All protocol modifications were
communicated to the relevant parties.
Amendment
In February 2016 an amendment was implemented after
notification and approval by the regulatory authorities.
Trial status
Recruiting.
Estimated enrollment: 172 including estimated 10 % loss
of follow-up.
Study start date: August 2015.
Study completion date: December 2017.
Sponsor
Universitätsklinikum Jena, Bachstrasse 18, 07745 Jena,
Germany.
Discussion
Multiple randomized “first-in-man” trials and registries
[3, 4, 8, 9] of first-generation drug-coated balloon tech-
nology have convincingly demonstrated the superiority
of paclitaxel-coated DEB angioplasty compared to
POBA in relation to LLL, restenosis rate and freedom
from TLR. In line, a meta-analysis including 381 pa-
tients overall (DEB angioplasty N = 186 versus POBA
N = 195) confirmed angiographically the superiority of
paclitaxel-coated DEB angioplasty in reducing significantly
the TLR rate (12.2 % versus 27.7 %, respectively) and the
restenosis rate (18.7 % versus 45.5 %, respectively) com-
pared to POBA [10]. Interestingly, up to now only drug-
eluting devices for peripheral interventions based on
paclitaxel-coated technology have demonstrated clinical
benefit. There are nine RCTs comparing paclitaxel-coated
DEB angioplasty versus POBA, five of them industry-
sponsored. A total of 1448 patients were recruited
(range, 50 to 479). The most common primary endpoint is
“late lumen loss” (LLL) at 6 months. Seven out of nine
RCTs were core-laboratory adjudicated for primary out-
come assessment (Table 2) [3–5, 8, 11–17]. First, pacli-
taxel (3 μg/m2) was combined with iopromide as an
excipient (Paccocath) [3, 4] followed by others such as
polysorbate and sorbitol (Lutonix 35, LEVANT I) [8] or
urea (IN.PACT Pacific, Pacifier®) [5] and butyryl-trihexyl
citrate carrier substances (Passeo Lux, Biolux P-1) [11].
After having demonstrated the proof of concept, two
RCTs followed: the IN.PACT SFA trial [12], using the
IN.PACT Admiral® (Medtronic, Santa Rosa, CA, USA)
balloon catheter (urea and 3.5 μg/m2 paclitaxel) and en-
rolling 331 patients revealed at 12 months a significantly
lower clinically driven TLR rate for DEB angioplasty
compared to uncoated POBA (2.4 % versus 20.6 %; p <
0.001) and a higher primary patency rate of 82.2 % for
DEB angioplasty versus 52.4 % for POBA; the second
trial (LEVANT II) [16] included 476 patients overall who
were treated with the Lutonix® (Bard, Covington, GA,
USA) paclitaxel-coated DEB angioplasty (polysorbate/
sorbitol and 2 μg/m2 paclitaxel). The primary patency at
12 months was favorable for paclitaxel-coated DEB
angioplasty (65.2 % versus 52.6 %; p = 0.02) and again
Table 2 Study overview of published RCTs applying paclitaxel-coated DEB angioplasty in the femoral and popliteal arteries
Study Author/Journal/Year Patients Study device Primary endpoint Sponsor
BIOLUX P-I [11] Scheinert D, JET 2015 60 Biotronik Passeo-18 LUX LLL 6 mo Biotronik
DEBATE-SFA [12] Liistro F, JACC 2013 104 Medtronic IN.PACT Admiral binary restenosis 12 mo Independent
DEBELLUM [13] Fanelli F, JCV 2014 50 Medtronic IN.PACT Admiral
or IN.PACT Amphirion
LLL 6 mo Independent
FemPac [3] Werk M, CIRC 2008 117 PACCOCATH LLL 6 mo Independent
IN.PACT SFA [14, 15] Tepe G, CIRC 2015;
Laird J, JACC 2015
331 Medtronic IN.PACT Admiral pP 12 mo Medtronic
LEVANT 1 [8] Scheinert D, JACC 2014 101 Bard Lutonix DCB LLL 6 mo Bard
LEVANT 2 [16] Rosenfield K, NEJM 2015 476 Bard Lutonix DCB pP 12 mo Bard
PACIFIER [5] Werk M, CIRC 2012 85 Medtronic IN.PACT Admiral LLL 6 mo Independent
THUNDER [4, 17] Tepe G, NEJM 2008,
JACC 2015
154 PACCOCATH LLL 6 mo Bavaria Medizintechnologie,
Schering
LLL late lumen loss, mo months, pP primary patency
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demonstrated a better outcome. However, at 12 months
freedom from clinically driven TLR in the LEVANT II
trial was not significantly improved compared to POBA
(87.7 % versus 83.2 %; p = 0.208). Again, both trials
confirmed that balloon-based paclitaxel drug-eluting
technology for treatment of TASC II types A and B
femoropopliteal artery lesions achieve promising clinical
1-year outcomes. Consistently, no signs of paclitaxel-
coated DEB angioplasty-associated side effects, including
amputation or distal embolization of the vascular bed,
were reported during follow-up in any of the studies. In
line, the Stellarex® paclitaxel-coated DEB catheter (Spec-
tranetics, Colorado Springs, CO, USA) was also shown to
be safe and effective with a lower paclitaxel concentration
(2 μg/m2 paclitaxel) according to recent 24-month data
released from the first in-man study (ILLUMINATE) [18].
In this prospective, multicenter, single-arm study 58 femor-
opopliteal artery lesions in 50 patients were treated and the
preliminary data revealed a primary patency rate of 80.3 %
and freedom from clinically driven TLR of 85.8 % with no
deaths or amputations at 24 months. Data from already-
initiated, randomized multicenter trials comparing Stel-
larex® paclitaxel-coated DEB angioplasty versus POBA are,
however, still ongoing.
As uncompromised drug delivery to the target lesion
in the vasculature is a major issue, strong efforts were
made to address this goal. For example, Boston Scientific
(Marlborough, MA, USA) has investigated the Ranger®
paclitaxel-coated DEB catheter. This device has a
proprietary trans-Pax coating® technology designed to
maintain drug-coating integrity and maximize drug
transfer efficiency. All the different paclitaxel-coated
DEB catheters available until now have in common
that their proprietary coating technology enables con-
sistent and predictable drug delivery to the vessel wall.
As mentioned above, the investigators of this trial
evaluated the concept of homogenous distribution of
paclitaxel 3 μg/cm2 on the balloon’s surface by applying
a proprietary Transfertech® coating technology. The drug
is deposited on the balloon’s surface by means of ultra-
sonographic exposure to guarantee a uniform diameter
in nanodrops to finally constitute an ultrathin multilayer
coating. This technology has been engineered to improve
clinical efficacy by optimizing coating properties and device
functionalities. In animal models, this concept showed
convincing results and promising first in-men studies
resulted in the CE mark being granted for the Luminor®
DEB catheter.
Overall, paclitaxel-coated DEB angioplasty is an in-
novative technology that offers multiple advantages and
follows a “leaving-nothing-behind” concept that main-
tains all future options open for further treatment. This
possibility fits well, as the natural course of peripheral
arterial disease is, unfortunately, progressive.
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